Telomir-1 shows copper-binding ability; Wilson's disease program advanced

Telomir Pharmaceuticals, Inc.

Preclinical studies show Telomir-1 strongly binds copper, targeting Wilson's disease caused by copper accumulation.
Company plans IND/INAD submission by Q4 2025, with clinical trials expected in 2026.
Telomir-1 also interacts with essential ions, potentially improving on current Wilson's treatments.
Telomir is advancing preclinical studies in Wilson's disease while exploring other copper-related conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.